Researchers at Stanford and UCSF have discovered a strong association between serious, potentially fatal, delayed hypersensitivity reactions that occur in a subset of patients exposed to IL-1/IL-6 inhibitors and HLA-DRB1*15 alleles that are common across ancestries.
Researchers at Stanford and the European Molecular Biology Laboratory (EMBL) have discovered an improved embodiment of bacterial retron-based CRISPR gene editing in mammalian cells.
Researchers at Stanford previously described a method under Stanford Docket S17-020 for introducing a large number of gene edits in parallel, termed Multiplexed Accurate Genome Editing with Short, Trackable, Integrated Cellular barcodes (MAGESTIC).
Stanford researchers have developed a geometric deep learning based novel method to aid in identification and discovery of novel drug scaffolds as well as to optimize known scaffolds, as a means to combat the major challenge in drug discovery.
Stanford researchers at Dr. Williams' Brain Stimulation Lab have developed a method to treat brain disorders such as traumatic brain injury using a naturally occurring psychoactive molecule found in plants called Ibogaine.
Stanford and Baylor researchers have discovered an exercise-induced lactate-derived metabolite that mediates the anorexigenic and anti-obesity effects of physical activity.
Researchers at Stanford University have discovered that the absence of a long non coding RNA (lnc122) predisposed mice to high numbers of hepatocellular carcinomas (HCC), and its replacement decreased the risk of HCC.
Stanford inventors have created a novel, interactive, highly scalable computational approach for representing dynamic brain activity as a network for use in clinical settings.
Stanford researchers have developed methods for optimizing peptide vaccines, with candidate peptides against EGFPvIII-expressing glioblastoma and SARS-CoV-2.
To combat the growing problem of antibiotic resistant bacteria, Stanford researchers have developed nanoclusters comprising a metallic core conjugated to a nucleotide.
One of the main shortcomings of the clinical use of Hematopoietic Stem Cells (HSCs) is the limited number of cells that can be safely harvested from a patient.